Skip to content

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia
Early-phase CLL trial shows bexobrutideg well tolerated
Radiation from medical imaging increases risk of blood cancers in children
BLA submitted to FDA for pivekimab sunirine in BPDCN
Dr. Kantarjian interviews Dr. Graff on MorningSun trial at SOHO 2025

Join SOHO

Follow Us :

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Novel therapy INCA in ET shows positive results in early-phase data

Cellular Therapy

Novel therapy INCA in ET shows positive results in early-phase data

Leukemia

Novel therapy INCA in ET shows positive results in early-phase data

Lymphoma

Novel therapy INCA in ET shows positive results in early-phase data

Multiple Myeloma

Novel therapy INCA in ET shows positive results in early-phase data

Myelodysplastic Syndromes

Novel therapy INCA in ET shows positive results in early-phase data

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

October 6, 2025

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Myeloproliferative Neoplasms

MPN News

EHA 2025 Myeloproliferative Neoplasms Video Interviews

Novel therapy INCA in ET shows positive results in early-phase data

by Leah Sherwood
July 18, 2025
0 Comments

EHA 2025

EHA 2025 Meetings / Conferences Myeloproliferative Neoplasms

Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’

by SOHO Insider Editors
June 13, 2025
0 Comments

SOHO Insider podcast

Myeloproliferative Neoplasms SOHO Insider Podcast

Drs. Kuykendall and Hobbs on MPN care in 2025

by Leah Sherwood
June 2, 2025
0 Comments

Rio de Janeiro, Brazil - September 10, 2020: ANVISA, National Health Surveillance Agency, on smartphone screen. In Brazil, it exercises sanitary control over all products and services

Myeloproliferative Neoplasms Polycythemia Vera News

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

by SOHO Insider Editors
March 25, 2025
0 Comments

Myeloproliferative Neoplasms

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

by SOHO Insider Editors
February 28, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

spleen

Myeloproliferative Neoplasms Primary Myelofibrosis

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

by SOHO Insider Editors
January 28, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Do driver mutations influence treatment outcomes in myelofibrosis?

by Leah Sherwood
January 10, 2025
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Orphan Drug Designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

by SOHO Insider Editors
January 6, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

by sohonews
November 8, 2024
0 Comments

1
2

Top Categories

Cellular Therapy

13

Leukemia

54

Lymphoma

56

Multiple Myeloma

44

Myelodysplastic Syndromes

17

Myeloproliferative Neoplasms

11

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Cellular Therapy

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Leukemia

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Lymphoma

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Multiple Myeloma

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Myelodysplastic Syndromes

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Mehta-Shah expanded background

BTK ‘degrader’ bexdeg shines in Waldenström macroglobulinemia

Doctor holding an ipad

Early-phase CLL trial shows bexobrutideg well tolerated

CT scan

Radiation from medical imaging increases risk of blood cancers in children

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.